Search company, investor...
Domain Therapeutics company logo

Domain Therapeutics

domaintherapeutics.com

Founded Year

2001

Stage

Series A - II | Alive

Total Raised

$91.67M

Last Raised

$42M | 7 mos ago

About Domain Therapeutics

Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and early development of small molecules targeting G-Protein Coupled Receptors (GPCRs). Domain Therapeutics discovers allosteric modulators by exploiting its DTect-All technology. The company's pipeline is composed of new chemical entities, ranging from hits to optimized leads for significant indications such as schizophrenia, Parkinson's disease, and diabetes. It is based in Illkirch-Strasbourg, France, and was founded in 2001.

Headquarters Location

Bioparc 850 Boulevard Sébastien Brant

Illkirch-Strasbourg, 67400,

France

+33 3 90 40 61 50

Missing: Domain Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Domain Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Domain Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Domain Therapeutics is included in 2 Expert Collections, including Diabetes.

D

Diabetes

1,899 items

B

Biopharma Tech

838 items

Domain Therapeutics Patents

Domain Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Amino acids
  • Analgesics
  • MGlu5 receptor antagonists
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/14/2018

10/18/2022

MGlu5 receptor antagonists, Amino acids, Pyridines, Metabotropic glutamate receptors, NMDA receptor antagonists

Grant

Application Date

5/14/2018

Grant Date

10/18/2022

Title

Related Topics

MGlu5 receptor antagonists, Amino acids, Pyridines, Metabotropic glutamate receptors, NMDA receptor antagonists

Status

Grant

Latest Domain Therapeutics News

Domain Therapeutics To Progress Into Clinical Trials With Its EP4R Antagonist DT-9081 In Solid Tumors

Oct 19, 2022

Clinical trial applications accepted in France and Belgium for initiation of Phase I clinical trial of DT-9081 Domain’s first fully owned immuno-oncology program to enter the clinic by end of 2022 Extensive biomarker strategy developed to optimize future clinical trials Strasbourg and Montreal, QC (GLOBE NEWSWIRE) - Domain Therapeutics (“Domain” or “the Company”), a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announces that its proprietary IO candidate, DT-9081, has cleared its clinical trial applications (CTA) by the ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) in France and the AFMPS (Agence Fédérale des Médicaments et des Produits de Santé) in Belgium, enabling Domain to start its Phase I clinical trial. The first-in-human clinical trial is on track to initiate by the end of the year. DT-9081 is an oral small molecule drug candidate, which is able to reverse the prostaglandin E2 (PGE2)-mediated immunosuppression triggered by some tumors to bypass the immune system, by blocking the EP4 receptor present on immune cells. Given the high concentrations of PGE2 exhibited by a range of different solid tumors, Domain Therapeutics has developed an extensive biomarker strategy, enabling optimal selection of tumor types and patient subpopulations and monitoring the target engagement in future clinical trials. Furthermore, this approach will help in finalizing the design of future clinical trials, in combination with standard of care including immune checkpoint inhibitors (such as anti-PD1). Dr. Pascal Neuville, CEO of Domain Therapeutics, commented: “Today’s news marks a pivotal moment for Domain as we progress our first fully-owned immuno-oncology drug candidate towards the clinic. Our proprietary assets in immuno-oncology are selected through a rigorous approach that utilizes our unrivalled expertise of GPCRs. We believe that DT-9081 has the potential to be a best-in-class therapeutic with multi-tumor applications. We look forward to dosing our first patient by the end of this year.” Dr. Asmaa Boudribila, Medical Director at Domain Therapeutics, commented: “DT-9081 is a promising new candidate with the potential to treat a wide range of cancers. The signals and strong synergies with immune checkpoint inhibitors observed in preclinical studies strengthen our belief that DT-9081 could potentially be a game-changer in immuno-oncology therapies for cancer patients and we now look forward to progressing our first clinical milestone.” About Domain Therapeutics Domain Therapeutics, a biopharmaceutical company operating in France and Canada, focuses on the discovery and development of new drug candidates targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes. The Company develops high-value drug candidates to address GPCR-mediated immunosuppression in immuno-oncology and raised €39m in early 2022. www.domaintherapeutics.com

Domain Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Domain Therapeutics Rank

Domain Therapeutics Frequently Asked Questions (FAQ)

  • When was Domain Therapeutics founded?

    Domain Therapeutics was founded in 2001.

  • Where is Domain Therapeutics's headquarters?

    Domain Therapeutics's headquarters is located at Bioparc, Illkirch-Strasbourg.

  • What is Domain Therapeutics's latest funding round?

    Domain Therapeutics's latest funding round is Series A - II.

  • How much did Domain Therapeutics raise?

    Domain Therapeutics raised a total of $91.67M.

  • Who are the investors of Domain Therapeutics?

    Investors of Domain Therapeutics include Seventure Partners, Omnes Capital, Turenne Group, Schroders Capital, CTI Life Sciences Fund and 25 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.